Skip to main content
. 2017 Nov 16;2017(11):CD004863. doi: 10.1002/14651858.CD004863.pub5

Analysis 3.7.

Analysis 3.7

Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 7 BASC‐2 composite score at 3.5 to 4 years ‐ externalising problems.